@pubmed.ncbi.nlm.nih.gov.rss-feed.feed.id.1bkd3nt7c-bb2ox2p4gq17anukdwtgc2lcfjxpodg3qewx1czi.utm.content.1bkd3nt7c-bb2ox2p4gq17anukdwtgc2lcfjxpodg3qewx1czi.utm.medium.rss.ff.20260423180744.utm.source.rss-parrot-bot.v.2.19.0.post6.133c1fe@rss-parrot.net
I'm an automated parrot! I relay a website's RSS feed to the Fediverse. Every time a new post appears in the feed, I toot about it. Follow me to get all new posts in your Mastodon timeline! Brought to you by the RSS Parrot.
---
Multiple [TIAB] AND sclerosis [TIAB] AND therapy [TIAB] AND trial: Latest results from PubMed
Feed URL: pubmed.ncbi.nlm.nih.gov/rss/search/1BKD3NT7c-BB2OX2P4gq17ANUKDwTGC2lCFjxpodg3qEwx1cZI/
Posts: 12
Followers: 1
Reduced Paramagnetic Rim Visibility Signals Lesion Aging and Tissue Degeneration in Progressive Multiple Sclerosis: Impact on Clinical Trials
Published: September 21, 2026 10:00
BACKGROUND AND OBJECTIVES: Paramagnetic rim lesions (PRLs) in multiple sclerosis (MS) indicate chronic, innate immune-mediated inflammation contributing to disease progression. Rim disappearance or attenuation is interpreted as a treatment response;…
Therapeutic Efficacy of Mesenchymal Stem Cells at the Level of Biomarkers in Multiple Sclerosis: A Systematic Review
Published: September 20, 2026 10:00
Multiple sclerosis (MS), particularly progressive forms, remains a significant therapeutic challenge. Mesenchymal stem cell (MSC) therapy offers promising immunomodulatory and neuroprotective potential. This systematic review comprehensively evaluates the…
A novel therapeutic regimen based on the constrained-disorder principles may improve the response to dimethyl fumarate in multiple sclerosis: Findings from an exploratory feasibility open-label clinical trial
Published: September 17, 2026 10:00
INTRODUCTION: Dimethyl fumarate (DMF) is an oral disease-modifying therapy recommended for patients with relapsing-remitting multiple sclerosis (MS). However, a lack of efficacy, safety concerns, tolerability issues, and poor compliance often lead to…
Exploring Healthcare Continuity in Pediatric-Onset Multiple Sclerosis in the United States
Published: September 17, 2026 10:00
CONCLUSION: Variable transition-of-care practices and barriers were reported by major US POMS centers. Before typical transition age, age ≥ 18 was associated with greater hazard of 1- and 2-year follow-up lapse than < 18. Developing standardized, targeted…
Application of Mesenchymal Stromal Cells and Their Exosomes in Neurodegenerative Diseases and Lysosomal Storage Diseases
Published: September 15, 2026 10:00
Mesenchymal stromal cells (MSCs) have emerged as a promising therapeutic platform for central nervous system disorders, including neurodegenerative diseases and lysosomal storage disorders (LSDs). This review examines MSC mechanisms of action-paracrine…
Efficacy and safety of autologous hematopoietic stem cell transplantation (AHSCT) versus alemtuzumab in multiple sclerosis: Systematic review and individual patient data meta-analysis
Published: September 14, 2026 10:00
CONCLUSIONS: AHSCT may be associated with improved inflammatory disease control and disability recovery compared with alemtuzumab in highly active MS. However, given the very low certainty of the evidence and the reliance on observational data, these…
Age and treatment class modify inflammatory risk after disease-modifying therapy discontinuation in older people with MS
Published: September 14, 2026 10:00
CONCLUSIONS: In people with MS aged ≥50 years, the inflammatory consequences of DMT discontinuation, mainly driven by MRI, are modified by age, with attenuation in those aged >60 years and no associated increase in mid-term disability progression.
Recognition and management of acute relapse of multiple sclerosis, neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease
Published: September 12, 2026 10:00
Autoimmune diseases of the central nervous system include multiple sclerosis (MS) and an ever-expanding spectrum of related disorders, such as neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated…
Disease-modifying therapy uptake in a pediatric-onset multiple sclerosis population, British Columbia, Canada
Published: September 11, 2026 10:00
CONCLUSIONS: Moderate-efficacy therapies were the more common initial DMT dispensed for individuals with POMS, but more than two-thirds eventually received a high-efficacy therapy. Only a minority of POMS cases were first dispensed a DMT under age 18…
Use of subcutaneous natalizumab in routine care - Final results of a non-interventional, observational study (SISTER) in Germany and Austria
Published: September 10, 2026 10:00
CONCLUSIONS: The final SISTER results suggest a patient preference for the SC vs. IV route and support the outcomes of the NOVA Part 2 trial, in which the preference of the SC route over IV was demonstrated in a cross-over design. The SC route allowed…
Evaluation of MRI asymptomatic gadolinium-enhancing lesions conversion to persistent black hole with high-dose methylprednisolone pulse therapy in relapsing remitting multiple sclerosis patients: a randomized trial
Published: September 9, 2026 10:00
CONCLUSIONS: Intravenous methylprednisolone pulse therapy administered for asymptomatic gadolinium-enhancing lesions was not associated with a statistically significant reduction in the formation of chronic T1 black holes over a 6-month follow-up period.
A group resilience training program for people with multiple sclerosis: A cluster-randomized controlled trial (multi-READY for MS)
Published: September 8, 2026 10:00
CONCLUSIONS: READY was not superior for the primary endpoint but was superior for most secondary outcomes.